Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 24;2(2):135-145.
doi: 10.1016/j.jacbts.2017.01.007. eCollection 2017 Apr.

Ticagrelor Removal From Human Blood

George O Angheloiu  1   2   3 , Gabriel B Gugiu  4 , Cristian Ruse  5 , Rishikesh Pandey  1 , Ramachandra R Dasari  1 , Carl Whatling  6
Affiliations

Ticagrelor Removal From Human Blood

George O Angheloiu et al. JACC Basic Transl Sci. .

Abstract

The authors devised an efficient method for ticagrelor removal from blood using sorbent hemadsorption. Ticagrelor removal was measured in 2 sets of in vitro experiments. The first set was a first-pass experiment using bovine serum albumin (BSA) solution pre-incubated with ticagrelor, whereas the second set, performed in a recirculating manner, used human blood mixed with ticagrelor. Removal of ticagrelor from BSA solution reached values >99%. The peak removal rate was 99% and 94% from whole blood and 99.99% and 90% from plasma during 10 h and 3 to 4 h of recirculating experiments, respectively. In conclusion, hemadsorption robustly removes ticagrelor from BSA solution and human blood samples.

Keywords: BSA, bovine serum albumin; CABG, coronary artery bypass graft; P2Y12; b.i.d., twice a day; concentration; drug; platelet; removal; sorbent; ticagrelor.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Experimental Setup for Ticagrelor Removal From BSA Solution and Human Blood Experimental setup for ticagrelor removal from BSA solution (A) and human blood (B). BSA, bovine serum albumin.
Figure 2
Figure 2
Removal Rate of Ticagrelor From a 4% BSA Solution Removal rate of ticagrelor from a 4% BSA solution using various volumes of sorbent—CytoSorb (A) and Porapak Q 50-80 mesh (B)—in a first-pass experiment. Abbreviation as in Figure 1.
Figure 3
Figure 3
Removal Rate of Ticagrelor From Whole Human Blood Removal rate of ticagrelor from whole human blood purchased from a blood bank during a recirculating experiment using CytoSorb in 2 models, on 14 10-ml columns mounted in series (model 1) (A) or 1 300-ml column (model 2) (B).
Figure 4
Figure 4
Removal Rate of Ticagrelor From Whole Human Blood and Plasma Removal rate of ticagrelor from whole human blood (A) and plasma (B) freshly (<60-min interval until being used) collected during model 3 of the blood recirculating experiment using CytoSorb.
Figure 5
Figure 5
Comparison of Ticagrelor and AR-C124910XX Structures Comparison of ticagrelor (A) and main metabolite AR-C124910XX (B) structures.
See this image and copyright information in PMC

References

    1. Wallentin L., Becker R.C., Budaj A., for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. - PubMed
    1. Ebrahimi R., Dyke C., Mehran R. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009;53:1965–1972. - PubMed
    1. Held C., Asenblad N., Bassand J.P. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–684. - PubMed
    1. Cheng V.E., Oppermen A., Natarajan D., Haikerwal D., Pereira J. Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor. Heart Lung Circ. 2014;23:e115–e117. - PubMed
    1. Whitmore T.J., O'Shea J.P., Starac D., Edwards M.D., Waterer G.W. A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy. Chest. 2014;145:639–641. - PubMed

LinkOut - more resources